Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

DISEASE CHARACTERISTICS: * Men with a history of at least one male sexual partner * "Men" is defined as those documented "male" at birth (including male-to-female transgendered persons) * HIV-1 infection as documented by any federally approved, licensed HIV test performed in conjunction with screening (ELISA, western blot, or other approved test) * Alternatively, this documentation may include a record that another physician has documented that the patient has HIV based on prior ELISA and western blot, or other approved diagnostic tests * Meets one of the following sets of criteria: * Patients receiving antiretroviral therapy: * Receipt of antiretroviral therapy for at least 3 months prior to entry * No change in antiretroviral therapy within 30 days prior to entry * Patients not receiving antiretroviral therapy: * CD4-cell count ≥ 350 cells/mm³ within 90 days prior to study entry * No plans to start antiretroviral therapy prior to Week 28 * Normal anal cytological result, LSIL/condyloma, or ASCUS result within 90 days prior to entry, and no HGAIN on biopsy * No current or history of anal or peri-anal carcinoma * No anal cytological result of HSIL, atypical squamous cells suggestive of HSIL (ASC-H), or suggestive of invasive carcinoma at screening; or history of these results * No presence of penile or scrotal condyloma, LGAIN (condyloma or AIN 1), HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3), or invasive carc…